Announcements
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
- Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
More ▼
Key statistics
On Friday, Apellis Pharmaceuticals Inc (1JK:BER) closed at 35.75, 95.33% above the 52 week low of 18.30 set on Aug 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.67 |
---|---|
High | 37.68 |
Low | 35.71 |
Bid | 35.82 |
Offer | 36.57 |
Previous close | 37.71 |
Average volume | 77.90 |
---|---|
Shares outstanding | 121.37m |
Free float | 103.98m |
P/E (TTM) | -- |
Market cap | 4.76bn USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:30 BST.
More ▼